GSK2636771
Drug timelines are a Plus or Pro feature.
5 regulatory and trial events tracked for GSK2636771, covering 2018-07-24 to 2025-12-15. Get the full timeline:
Most recent: Clinical Trial Update: Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss [Phase 1, Phase 2]